To access this element change to forms mode OFF
Grant Award View - GA29908
Targeting MK2 to overcome glioblastoma resistance to therapy
GA ID:
GA29908
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2021
Value (AUD):
$667,029.40
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Targeting MK2 to overcome glioblastoma resistance to therapy
Purpose:
Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called MK2 (using ‘MK2 inhibitors’) improves chemotherapy outcomes. This project will examine a novel drug combination treatment for glioblastoma patients and generate evidence for initiation of clinical trials. This could initiate a novel therapy that could significantly extend patients’ lives.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1163484
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC
Postcode:
Multiple
Country:
AUSTRALIA